Clinical trials: Hepatitis C, Chronic
Hepatitis C Virus (HCV)
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
The objectives of this study are to assess the pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir adult formulation in adolescents ages 12 to 17 years and a pediatric formulation of glecaprevir and pibrentasvir in…
- Trial name
- DORA (NCT03067129)
- Testing
- Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
- Where
- 38 sites in United States, Belgium and 7 more
- Volunteers
- 129 people
- Sponsor
- AbbVie
Hepatitis C Virus Infection
Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection
This study will have 2 parts: Pharmacokinetics (PK) Lead-in Phase and the Treatment Phase. The primary objective of the PK Lead-in Phase is to evaluate the steady state PK and confirm the dose of sofosbuvir/velpatasvir (SOF/VEL)…
- Trial name
- NCT03022981
- Testing
- SOF/VEL
- Where
- 27 sites in United States, Belgium and 2 more
- Volunteers
- 216 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a…
- Trial name
- PEDESTAL (NCT01598090)
- Testing
- Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin
- Where
- 104 sites in United States, Austria and 13 more
- Volunteers
- 881 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children.
- Trial name
- NCT00100659
- Testing
- Pegylated Interferon/ribavirin
- Where
- 11 sites in United States
- Volunteers
- 114 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C,Chronic Children, Only
Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years
Recently the era of direct-acting antiviral drugs for hepatitis C treatment has changed the world map of HCV. Results in adults are promising. FDA approved only two drugs in the pediatric age group 12 to 17 years.
- Trial name
- NCT07905989
- Testing
- Sofosbuvir/Daclatasvir
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- National Liver Institute, Egypt
Hepatitis C
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs
Neuropsychiatric adverse effects of direct acting antiviral drugs, especially Sofosbuvir and Daclatasvir combination therapy (with or without ribavirin) in patients with chronic hepatitis C , genotype four (the predominant…
- Trial name
- NCT03268317
- Volunteers
- 100 people
- Sponsor
- Assiut University
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
The primary objective of the PK Lead-in Phase of the study is to evaluate the steady state pharmacokinetics (PK) and confirm the dose of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) in hepatitis C virus…
- Trial name
- NCT02249182
- Testing
- LDV/SOF, RBV
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 226 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic Hepatitis
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
The purpose of this study is to evaluate daclatasvir in combination with sofosbuvir given to children with chronic hepatitis C infection
- Trial name
- NCT03487848
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 2 sites in Australia, Spain
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus (HCV)
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
Hepatitis C virus (HCV) infection is among the most common of all chronic liver diseases. HCV predominantly affects liver cells and causes the liver to become inflamed and damaged.
- Trial name
- CHOICE (NCT04577482)
- Where
- 10 sites in Russia
- Volunteers
- 42 people
- Sponsor
- AbbVie
De Novo Autoimmune Hepatitis
De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation
The purpose of this study is to provide insights into the cause, development and effects of de novo autoimmune hepatitis so that prevention and treatment strategies can be developed in order to reduce post-liver transplant…
- Trial name
- NCT02056054
- Testing
- Pediatric transplant subject with d-AIH, Pediatric transplant subject with acute rejection, Pediatric transplant subject with chronic rejection
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Yale University
Liver Cancer
The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis
Previous data have suggested that vitamin D levels may influence cancer development. In particular, several single nucleotide polymorphisms have been described in the Vitamin D receptor( VDR gene), and some polymorphisms are…
- Trial name
- NCT02461979
- Testing
- The VDR genotype
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sherief Abd-Elsalam
Chronic Hepatitis C
Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)
This is a three-part (Part A, Part B, and Part C), open-label, multicenter study of boceprevir in pediatric participants with chronic hepatitis C (CHC) genotype 1 (GT1).
- Trial name
- NCT01590225
- Testing
- Boceprevir, Peginterferon alpha-2b, Ribavirin
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages
Background: The global response to the HCV infection epidemic has been transformed by the availability of low-cost curative short course direct acting antiviral (DAA) therapy.
- Trial name
- NCT04177043
- Testing
- HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests, DAAs
- Volunteers
- 221,855 people, healthy volunteers welcome
- Sponsor
- Egyptian Liver Hospital
Hepatitis C Genotype 4
Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir
This is an open, uncontrolled pilot study of thirty chronic HCV infected patients carried out at Yassin Abdel Ghaffar Charity Center for Liver Disease and Research.
- Trial name
- NCT03080415
- Testing
- Combined Therapy SOF and DCV
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Yassin Abdelghaffar Charity Center for Liver Disease and Research
Chronic Hepatitis C Infection
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
This is a multi-centre prospective longitudinal cohort study with the aim of collecting and storing clinical data, patient blood, DNA and PBMCs to examine outcomes related to drug resistance, drug monitoring and host genetics in…
- Trial name
- SEARCH-C (NCT02065999)
- Where
- 2 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Kirby Institute
Chronic Hepatitis C
Pharmacogenomics Study on IL28B Genetic Variants in Chinese Children With Hepatitis C Virus Infection
The aim of this study is to investigate the relationships between interleukin 28B genetic variants and the response to treatment of chronic hepatitis C in Chinese children.
- Trial name
- NCT01607021
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing 302 Hospital
Hepatitis C, Chronic
Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan
To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan
- Trial name
- NCT03200379
- Testing
- directly acting antivirals (DAAs)
- Where
- Taiwan
- Volunteers
- 150,000 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
HCC in Chronic HCV Patients With Advanced Liver Fibrosis
Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals
Chronic HCV infection has relatively slow rate of progression. Liver fibrosis is the main sequlae and usually progressed to cirrhosis after long period (10 to 20 years) [6].
- Trial name
- NCT03884062
- Testing
- DAAs
- Volunteers
- 3,000 people
- Sponsor
- Egyptian Liver Hospital
Fibrosis, Chronic Liver Disease
Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease
Hepatitis C virus (HCV) infection causes different disease spectrum ranging from minimal progressive liver disease to cirrhosis or hepatocellular carcinoma.
- Trial name
- NCT00629603
- Testing
- cytokine, cytokine polymorphisms, cytokine polymorphism
- Where
- 2 sites in Taiwan
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Chronic Hepatitis C
Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin
Genotype 1 CHC participants from Study SPC3649-207 with null response to prior pegylated-interferon alpha plus ribavirin will be enrolled into this 36-month extension study, designed to evaluate the long-term safety and efficacy…
- Trial name
- NCT02508090
- Where
- Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche